CompletedPhase 1NCT00118924
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
Studying Tick-borne encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Anna Durbin, MDCenter for Immunization Research, Johns Hopkins School of Public Health
- Intervention
- LGT(TP21)/DEN4(biological)
- Enrollment
- 28 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2005 – 2007
Study locations (1)
- Vanderbilt University School of Medicine, Nashville, Tennessee, United States
Collaborators
Johns Hopkins Bloomberg School of Public Health
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00118924 on ClinicalTrials.gov